Abstract： Objective To investigate the therapeutic efficacy of Jinshuibao capsules in the treatment of silicosis.Methods A total of 270 patients with silicosis were randomly divided into treatment group (n=141) and control group (n=129).Both groups received conventional therapy.Additionally,the patients in the treatment group took 3 Jinshuibao capsules three times a day for 2-3 courses of treatment (each course=6 weeks).The therapeutic efficacy and the changes in tumor necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) levels were observed after treatment.Results After treatment,cough,expectoration,chest pain,shortness of breath,and other respiratory symptoms were relieved significantly (P＜0.05).The treatment group showed significantly lower TNF-α and TGF-β1 levels than before treatment and the control group (P＜0.05) and significantly higher forced vital capacity,forced expiratory volume in one second,and maximum mid-expiratory flow than before treatment and the control group (P＜0.05).Conclusion Jinshuibao capsules can decrease inflammatory response,increase vital capacity and maximum voluntary ventilation,reduce airflow limitation,and improve quality of life and thus have good therapeutic efficacy in the treatment of silicosis.